TRACON Pharmaceuticals, Inc. (TCON)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 18.92 Million USD | -32.14% |
| 2022 | 27.89 Million USD | -2.78% |
| 2021 | 28.69 Million USD | 76.87% |
| 2020 | 16.22 Million USD | -27.24% |
| 2019 | 22.29 Million USD | -40.92% |
| 2018 | 37.74 Million USD | 39.96% |
| 2017 | 26.96 Million USD | -8.36% |
| 2016 | 29.42 Million USD | -6.2% |
| 2015 | 31.37 Million USD | 220.87% |
| 2014 | 9.77 Million USD | 29.33% |
| 2013 | 7.56 Million USD | 44.66% |
| 2012 | 5.22 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 3.3 Million USD | 25.54% |
| 2024 Q2 | 2.96 Million USD | -10.31% |
| 2023 Q1 | 7.31 Million USD | 25.39% |
| 2023 Q4 | 2.63 Million USD | -26.56% |
| 2023 FY | 18.92 Million USD | -32.14% |
| 2023 Q3 | 3.58 Million USD | -63.31% |
| 2023 Q2 | 9.77 Million USD | 33.72% |
| 2022 FY | 27.89 Million USD | -2.78% |
| 2022 Q4 | 5.83 Million USD | -8.55% |
| 2022 Q3 | 6.37 Million USD | 2.21% |
| 2022 Q2 | 6.23 Million USD | -33.95% |
| 2022 Q1 | 9.44 Million USD | 23.27% |
| 2021 Q2 | 9.19 Million USD | 85.55% |
| 2021 Q4 | 7.66 Million USD | 11.36% |
| 2021 Q1 | 4.95 Million USD | 18.63% |
| 2021 Q3 | 6.88 Million USD | -25.16% |
| 2021 FY | 28.69 Million USD | 76.87% |
| 2020 Q4 | 4.17 Million USD | 8.55% |
| 2020 Q1 | 3.88 Million USD | 1.89% |
| 2020 Q2 | 4.31 Million USD | 11.07% |
| 2020 Q3 | 3.84 Million USD | -10.8% |
| 2020 FY | 16.22 Million USD | -27.24% |
| 2019 FY | 22.29 Million USD | -40.92% |
| 2019 Q4 | 3.81 Million USD | -24.98% |
| 2019 Q2 | 6.24 Million USD | -12.89% |
| 2019 Q3 | 5.08 Million USD | -18.57% |
| 2019 Q1 | 7.16 Million USD | -7.35% |
| 2018 Q1 | 11.18 Million USD | 76.09% |
| 2018 Q4 | 7.73 Million USD | -14.88% |
| 2018 FY | 37.74 Million USD | 39.96% |
| 2018 Q3 | 9.08 Million USD | -6.72% |
| 2018 Q2 | 9.73 Million USD | -12.98% |
| 2017 Q3 | 6.1 Million USD | -12.31% |
| 2017 Q1 | 7.54 Million USD | 12.76% |
| 2017 Q2 | 6.96 Million USD | -7.75% |
| 2017 FY | 26.96 Million USD | -8.36% |
| 2017 Q4 | 6.35 Million USD | 4.1% |
| 2016 Q1 | 7.5 Million USD | -38.65% |
| 2016 FY | 29.42 Million USD | -6.2% |
| 2016 Q4 | 6.69 Million USD | 4.37% |
| 2016 Q3 | 6.41 Million USD | -27.28% |
| 2016 Q2 | 8.81 Million USD | 17.5% |
| 2015 Q2 | 6.88 Million USD | 42.05% |
| 2015 Q1 | 4.84 Million USD | 47.1% |
| 2015 FY | 31.37 Million USD | 220.87% |
| 2015 Q4 | 12.23 Million USD | 64.95% |
| 2015 Q3 | 7.41 Million USD | 7.76% |
| 2014 Q1 | 1.68 Million USD | -21.42% |
| 2014 Q2 | 1.96 Million USD | 16.11% |
| 2014 Q3 | 2.83 Million USD | 44.69% |
| 2014 Q4 | 3.29 Million USD | 16.11% |
| 2014 FY | 9.77 Million USD | 29.33% |
| 2013 Q1 | 941 Thousand USD | 0.0% |
| 2013 Q3 | 927.99 Thousand USD | 5.82% |
| 2013 FY | 7.56 Million USD | 44.66% |
| 2013 Q2 | 877 Thousand USD | -6.8% |
| 2013 Q4 | 2.14 Million USD | 131.47% |
| 2012 FY | 5.22 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| America Great Health | 661.23 Thousand USD | -2762.687% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | -104.24% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | 36.889% |
| Biora Therapeutics, Inc. | 67.14 Million USD | 71.81% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -19.479% |
| Better Therapeutics, Inc. | 38.26 Million USD | 50.528% |
| Calithera Biosciences, Inc. | 40.68 Million USD | 53.479% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -52.743% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | 44.07% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | 45.004% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 82.548% |
| Evolutionary Genomics, Inc. | 992.8 Thousand USD | -1806.61% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | 41.916% |
| Galera Therapeutics, Inc. | 46.95 Million USD | 59.683% |
| Innovation1 Biotech Inc. | 1.21 Million USD | -1458.343% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | 5.067% |
| Molecular Templates, Inc. | 63.09 Million USD | 69.997% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | -35.871% |
| NexImmune, Inc. | 28.16 Million USD | 32.798% |
| Orgenesis Inc. | 45.75 Million USD | 58.631% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | 26.194% |
| Point of Care Nano-Technology, Inc. | 73.41 Thousand USD | -25683.208% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -17.242% |
| Scopus BioPharma Inc. | 11.71 Million USD | -61.581% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 95.31% |
| Statera Biopharma, Inc. | 28.82 Million USD | 34.342% |
| Trevena, Inc. | 38.41 Million USD | 50.722% |
| Vaxxinity, Inc. | 56.05 Million USD | 66.229% |
| Vaccinex, Inc. | 23.45 Million USD | 19.297% |
| Vicapsys Life Sciences, Inc. | 1.04 Million USD | -1707.965% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | 62.66% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -160.206% |